217 related articles for article (PubMed ID: 12065513)
1. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses.
Berry DS; Lynn F; Lee CH; Frasch CE; Bash MC
Infect Immun; 2002 Jul; 70(7):3707-13. PubMed ID: 12065513
[TBL] [Abstract][Full Text] [Related]
2. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
[TBL] [Abstract][Full Text] [Related]
3. Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C.
Moe GR; Bhandari TS; Flitter BA
J Immunol; 2009 May; 182(10):6610-7. PubMed ID: 19414816
[TBL] [Abstract][Full Text] [Related]
4. Structure of a protective epitope reveals the importance of acetylation of
Henriques P; Dello Iacono L; Gimeno A; Biolchi A; Romano MR; Arda A; Bernardes GJL; Jimenez-Barbero J; Berti F; Rappuoli R; Adamo R
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29795-29802. PubMed ID: 33158970
[TBL] [Abstract][Full Text] [Related]
5. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.
Fusco PC; Farley EK; Huang CH; Moore S; Michon F
Clin Vaccine Immunol; 2007 May; 14(5):577-84. PubMed ID: 17376859
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
10. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
11. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines.
Sikkema DJ; Friedman KE; Corsaro B; Kimura A; Hildreth SW; Madore DV; Quataert SA
Clin Diagn Lab Immunol; 2000 Sep; 7(5):764-8. PubMed ID: 10973451
[TBL] [Abstract][Full Text] [Related]
13. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
[TBL] [Abstract][Full Text] [Related]
14. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.
Park IH; Lin J; Choi JE; Shin JS
Mol Immunol; 2014 Jun; 59(2):142-53. PubMed ID: 24603121
[TBL] [Abstract][Full Text] [Related]
18. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
Devi SJ; Zollinger WD; Snoy PJ; Tai JY; Costantini P; Norelli F; Rappuoli R; Frasch CE
Infect Immun; 1997 Mar; 65(3):1045-52. PubMed ID: 9038314
[TBL] [Abstract][Full Text] [Related]
20. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
